T1	Outcomes 830 844	well tolerated
T2	Outcomes 853 891	drug-attributed serious adverse events
T3	Outcomes 924 1009	were upper respiratory tract infection, headache, and back pain, all mild to moderate
T4	Outcomes 1046 1078	a mild hypersensitivity reaction
T5	Outcomes 1108 1173	demonstrated slight enlargement of a preexisting midbrain lesion.
T6	Outcomes 1174 1231	Electrocardiography and laboratory values (including CSF)
T7	Outcomes 1266 1326	new microhemorrhage, vasogenic edema, or meningoencephalitis
T8	Outcomes 1425 1477	the area under the plasma concentration-time profile
T9	Outcomes 1582 1583	.
T10	Outcomes 1584 1607	Mean terminal half-life
T11	Outcomes 1663 1702	measurable CSF ponezumab concentrations
T12	Outcomes 1797 1809	and mean CSF
